Accuray reports 10 percent xerostomia rate with over 70 months follow up in helical TomoTherapy study

Accuray reports 10 percent xerostomia rate with over 70 months follow up in helical TomoTherapy study
Accuray TomoTherapy study data

Accuray has released prospective data from a study involving 266 patients with more than 70 months of follow up, indicating that comprehensive salivary gland sparing helical TomoTherapy may significantly reduce xerostomia rates to around 10 percent for grade 2 or higher and just 0.4 percent for grade 3, while also maintaining strong outcomes.

The research noted a five year locoregional recurrence free survival (LRRFS) of 92 percent and an overall survival (OS) of 81 percent, with no evidence of compromised tumor control. These findings could influence future approaches to radiation therapy for head and neck cancer.

Accuray recently presented on the integration of AI in radiotherapy at ESTRO, focusing on clinical performance and ethical considerations in cancer care, according to company statements. Earlier, the company reported that Myanmar’s National Cancer Center treated 18 patients in two days following the launch of its Radixact system at the facility. These developments reflect Accuray’s continued expansion in both technology and clinical deployment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.